You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Blind/Blindness Articles
Popular Blind/Blindness Articles
Highly Recommended Blind/Blindness Articles
Send a link to this page to your friends and colleagues.
With tens of millions of American facing life with type 2 diabetes and many millions more at risk of the disease, scientists are scrambling to unravel novel treatments. The latest breakthrough could come from California's Salk Institute.
Researchers there have focused on two tiny molecules that form a switch regulating glucose production in the liver. "If you control these switches, you can control the production of glucose, which is really at the heart of the problem of type 2 diabetes," said the Salk Institute's Marc Montminy.
Montminy's research has long focused on a genetic switch known as CRTC2. For people with type 2, said Montminy, "the CRTC2 switch is turned on too strongly because the insulin signal is not getting through. As a result, the liver produces too much glucose, and the level of glucose in the bloodstream is too high. Over a period of 10 to 20 years, the abnormal elevation of glucose leads to chronic complications, including heart disease, blindness, and kidney failure."
Montminy's new work has identified the molecular mechanism that turns the CRTC2 switch on full blast. When activated by the fasting hormone glucagon, the molecules form a feedback loop that drives the production of blood sugar.
The potential applications are clear. If the CRTC2 switch could be turned off or even turned down, the production of blood sugar in insulin-resistant patients could be slowed. And if the creation of blood glucose were slowed, diabetic symptoms and complications could be reduced.
It sounds very promising, but, as Montminy said, "We obviously have a lot of work to do to find out whether such a strategy might work in humans."
The research was published in the journal Nature. Along with researchers from the Salk Institute, scientists from Columbia University, the University of California San Diego, and the University of Ottawa contributed to the paper.
Categories: Blind/Blindness, Blood Sugar, Columbia University, CRTC2, Diabetes, Diabetes, Diabetes Health, Glucagon, Glucose, Insulin, Kidney Care (Nephropathy), Liver , Liver, New Treatments, Research, Salk Institute, Type 2 Diabetes, Type 2 Issues, University of California San Diego, University of Ottawa
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.